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Abstract
Schwann cell development is hallmarked by the induction of a lipogenic profile. Here we used amniotic fluid stem (AFS)
cells and focused on the mechanisms occurring during early steps of differentiation along the Schwann cell lineage.
Therefore, we initiated Schwann cell differentiation in AFS cells and monitored as well as modulated the activity of the
mechanistic target of rapamycin (mTOR) pathway, the major regulator of anabolic processes. Our results show that mTOR
complex 1 (mTORC1) activity is essential for glial marker expression and expression of Sterol Regulatory Element-Binding
Protein (SREBP) target genes. Moreover, SREBP target gene activation by statin treatment promoted lipogenic gene
expression, induced mTORC1 activation and stimulated Schwann cell differentiation. To investigate mTORC1 downstream
signaling we expressed a mutant S6K1, which subsequently induced the expression of the Schwann cell marker S100b, but
did not affect lipogenic gene expression. This suggests that S6K1 dependent and independent pathways downstream of
mTORC1 drive AFS cells to early Schwann cell differentiation and lipogenic gene expression. In conclusion our results
propose that future strategies for peripheral nervous system regeneration will depend on ways to efficiently induce the
mTORC1 pathway.
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Introduction
Specialized glial cells, known as Schwann cells, are essential for
correct development as well as maintenance of the peripheral
nervous system (PNS) [1]. Most importantly, Schwann cells are
needed for regeneration and repair of nerve lesions, because in
case of nerve damage, glial cells remyelinate regenerating axons
and guide the growing axons to their targets [2,3,4]. However,
adult Schwann cells are hardly available for cell-based regener-
ation approaches due to strong donor site morbidity after cell
isolation and due to their slow in vitro proliferation characteristics.
Therefore, amniotic fluid stem (AFS) cells are candidates as a
novel stem cell source for Schwann cell differentiation. Since the
discovery of Oct4-positive cells within human amniotic fluid [5],
several studies have reported the broadly multipotent potential of
these cells [6,7,8,9]. Immunoselection for c-kit has been shown to
be sufficient to yield cells which have the potential to differentiate
towards adipogenic, osteogenic, myogenic, endothelial, hepatic
and neurogenic lineages [10]. Importantly, c-kit-selected AFS cells
can be grown continuously in culture maintaining a stable
karyotype and exhibiting high proliferative capacity [10,11].
While mesenchymal stem cells from the bone marrow of rats
and humans were successfully differentiated towards Schwann
cells [12,13], it is currently unknown whether also monoclonal
human c-kit and Oct4-positive immuno-selected AFS cells harbor
the potential to give rise to Schwann cells.
During the course of early development, Schwann cells not only
express lineage restricted differentiation markers such as nerve
growth factor receptor (NGFR), glial fibrillary acidic protein
(GFAP) and S100b, but also up-regulate lipogenic gene expression
[14,15]. SREBP family transcription factors are the main
regulators of lipogenic genes, which include the low density
lipoprotein receptor (LDLR) and enzymes like HMG-CoA
reductase (HMGCR) and NAD(P) dependent steroid dehydroge-
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nase like (NSDHL) [16]. Recently, mTORC1 was suggested to be
involved in SREBP activation [17] and it was shown that
conditional deletion of mTOR in mice resulted in a reduced
myelin production by Schwann cells and reduced nerve conduc-
tion [1]. The underlying mechanism, however, is still unclear.
In the present study we investigated whether monoclonal
human AFS cells can be used to generate early Schwann cells and
analyzed the role of mTORC1 during this process. We applied a
novel protocol to differentiate Schwann cells from AFS cells and
demonstrated that inhibition of mTORC1 efficiently blocks
Schwann cell differentiation, whereas induction of lipogenic genes
stimulated Schwann cell differentiation.
Materials and Methods
Cells, cell culture of human AFS cells
The monoclonal human amniotic fluid stem (AFS) cell line Q1
and a high Oct4 expressing single cell clone derived from the
CD117/2 population was used in the study [10,11,18]. Cells were
maintained in a-MEM (Gibco-Invitrogen, USA) supplemented
with 15% Fetal Bovine Serum (HyClone, USA), 18% Chang B,
2% Chang C (Irvine Scientific, USA), 2.5 mM L-Glutamine (PAA,
Austria), 50 mg/L streptomycin sulphate (PAA, Austria) and
30 mg/L penicillin (PAA, Austria). For neural crest marker
expression melanoma-derived MCM1 cells were used as positive
control [19]. All cells were cultivated at 37uC in 5% CO2.
Differentiation of human AFS cells into a Schwann cell
phenotype
To initiate human AFS cells differentiation into a Schwann cell
phenotype, AFS cells were dissociated (80–90% confluence) with
0.25% trypsin/EDTA (PAA, Austria) and subsequently plated on
6 cm plastic dishes at a concentration of 105/cm2 in media
consisting of a-MEM and 1 mM b-mercaptoethanol (Sigma-
Aldrich, USA). After 24 hours, media was removed, cells were
washed with PBS (PAA, Austria) for 3 times, and media consisting
of a-MEM, 10% Fetal Bovine Serum (PAA, Austria) and 35 ng/
ml retinoic acid (Sigma-Aldrich, USA) was added. After 72 hours,
cells were washed with PBS for 3 times and media was replaced
with differentiation media consisting of a-MEM, 10% Fetal
Bovine Serum (PAA, Austria), 20 ng/mL epidermal growth factor
(EGF; Peprotech, UK), 20 ng/mL basic fibroblast growth factor
(bFGF; Peprotech, UK), 5 mM forskolin (Sigma-Aldrich, USA),
5 ng/mL platelet-derived growth factor-AA (PDGF-AA; Pepro-
tech, UK) and 200 ng/mL recombinant human heregulin-beta1
(HRG; Peprotech, UK). Media were additionally supplemented
with 2.5 mM L-Glutamine, 50 mg/L streptomycin sulphate and
30 mg/L penicillin. Differentiation media was changed every 3
days. Cells were cultivated at 37uC in 5% CO2. The cells were
incubated for another 10 days under these conditions and then
harvested for further investigation.
Animals
7 week-old C57BL/6 mice were treated daily with solvent
control (2.5% DMSO in H2O) or the mTORC1 inhibitor
everolimus (5 mg/kg body weight) for 4 weeks by oral gavage
(n = 6 for the solvent control, n = 7 for everolimus treatment).
Everolimus was a kind gift of Novartis. The animal study protocol
was performed in accordance with national laws and guidelines
and was approved by the Medical University of Vienna’s
Institutional Review Board (BMWF-66.009/0304-II/3b/2013).
All animal sacrifice was performed under ketamine/rompun
anesthesia, and all efforts were made to minimize suffering and
the number of animals used.
Transient transfection for gene overexpression
The HA-S6K1-RR construct used in this study was purchased
via Addgene (Cambridge, MA, USA): HA-S6K1-F5A-E389-R3A,
rapamycin-resistant/constitutively active. The differentiated AFS
cells on day 15 were transfected with HA-S6K1-RR plasmid using
Lipofectamine 2000 transfection reagent (Invitrogen, USA) and
cells were kept in differentiation media for another 72 hours.
Immunofluorescence staining
Cells cultured on chamber slides or 48-well plate were fixed in
4% (w/v) paraformaldehyde at room temperature for 30 min.
After fixation, cells were treated with PBS containing 0.1% Triton
X-100 for 5 min at room temperature and then blocked with PBS
containing 1% BSA for 30 min. Subsequently cells were incubated
with primary antibodies diluted in PBS containing 1% BSA
overnight at 4uC. The following antibodies were used: anti-NTR-
p75 (1:200; Santa Cruz Biotechnology, USA), anti-Glial Fibrillary
Acidic Protein (GFAP, 1:200; Santa Cruz Biotechnology, USA),
anti-S100b (1:10,000; Dako, Denmark), anti-nestin (1:500; Che-
micon, Temecula, CA, USA), anti-S6 ribosomal protein phos-
phorylated at S240/244 (1:1,000, Cell Signalling), anti-LDLR
(1:200; Santa Cruz Biotechnology, USA), anti-HMGCR (1:200; a
gift from Herbert Stangl). Subsequently cells were washed and
incubated with the secondary antibodies Alexa Fluor 546 goat
anti-mouse IgG (1:1,000; Invitrogen, USA) or Alexa Fluor 546
goat anti-rabbit IgG (1:1,000; Invitrogen, USA) at room temper-
ature for 1 hour. For visualizing nuclei, cells were stained with 6
diamidino-2-phenylindole dihydrochloride (DAPI, Sigma-Aldrich,
USA). The negative controls were generated by incubating with
isotype specific control antibodies and omitting the first-step
antibodies used in each experiment. Cells were observed using a
fluorescence microscope (Zeiss, Germany). Quantification of
immunofluorescence staining was performed by two independent
researchers who were blinded regarding experimental details. A
minimum of 250 cells per experiment were evaluated and cells
with a staining intensity stronger than the isotype control stain
were regarded as positive.
Histology
Sciatic nerves were isolated from C57BL/6 mice, fixed with 4%
(w/v) formaldehyde, dehydrated and embedded in paraffin. 4 mm
sections were used for Luxol fast blue staining by incubating
hydrated sections in 0.1% Luxol fast blue, 95% ethyl alcohol and
0.5% acetic acid at 56uC for 16 hours. The program ImageJ was
used to manually quantify 5 representative Luxol fast blue stained
cross sections per animal [20]. For myelin thickness the distance
between the inner and outer myelin diameter were measured and
for axonal packing the distance between the myelin wraps were
traced. A minimum of 100 myelinated axons were quantified per
animal. Immunohistochemistry was performed using modified
citrate buffer, pH 6.1 (Dako), for 20 min at 120uC for antigen
unmasking and 1% H2O2 for 15 min at room temperature to
quench endogenous peroxidases. Then the slides were blocked in
PBS containing 1% BSA for 20 min at room temperature and
slides were incubated with antibodies for S100b (1:10,000; Dako,
Denmark), nestin (1:500; Chemicon, Temecula, CA, USA) and S6
ribosomal protein S240/244 (1:1,000, Cell Signalling) over night
at 4uC and subsequently incubated with biotinylated secondary
antibodies and avidin biotin complexes conjugated with peroxi-
dase (Jackson Lab, West Grove, PA, USA) for 45 min at room
temperature. Aminoethyl carbazole (AEC, Dako) was used to
visualize the staining (20 min) and the slides were counterstained
with hematoxylin.
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RNA extraction and reverse transcription polymerase
chain reaction (RT-PCR) analysis of gene expression
Total RNA was extracted from either the mouse sciatic nerve
tissue or the AFS cells at different time points of differentiation
(day 0, 5, 8, 15) and conditions with RNeasy Mini Kit (Qiagen).
cDNA was synthesized from 5 mg total RNA using GoScript
Reverse Transcription System (Promega) according to the
manufacturer’s instructions. Real-time (SYBR Green) PCR was
performed using a CFX96 TouchTM Real-Time PCR Detection
System (Bio-Rad) with the following cycle conditions: 95uC for
2 min, 40 cycles at 95uC for 15 s, 60uC for 1 min. 5 ml GoTaq q
PCR Master Mix (Promega) and 1 ml cDNA for each reaction in
final volume of 10 ml were used. Human primers were used for
human AFS cells and mouse primers were used for the mouse
sciatic nerve tissue in RT-PCR. The sequences of primers used
were as follows: for human S100b: Forward 59- CGA ACT GAA
GGA GCT CAT CAA CAA-39, Reverse 59-AAC TCG TGG
CAG GCA GTA GTA ACC-39. For human nestin: Forward 59-
AGC AGG AGA AAC AGG GCC TAC AG-39, Reverse 59-CTG
AAA GCT GAG GGA AGT CTT GGA-39. For human
SREBF1: Forward 59-CGT CTC CTT GGT GCT TCT CTT
TGT-39, Reverse 59-GAT GAG GTT CCA GAG GAG GCT
ACA-39. For human SREBF2: Forward 59-ACT CTG AGC CAG
GAA GCC CTC TAT-39, Reverse 59-CAG AAC CTG ACT
CGA ATG ACA GGA-39. For human NSDHL: Forward 59-TCT
TCC CAT TTC CAA TCA CGA ACT-39, Reverse 59-TCT
TCC CAT TTC CAA TCA CGA ACT-39. For human LDLR:
Forward 59-TTT CTG GTT TCG GAG CAC GTA AAT-39,
Reverse 59-CAG AGG CAA TAA CCC CCT ACA CAG-39. For
human HMGCR: Forward 59-TCC AGA GCA AGC ACA TTA
GCA AAG-39, Reverse 59-GGA CAC ACA AGC TGG GAA
GAA AGT-39. For human Beta Actin: Forward 59-CTA TCC
AGG CTG TGC TAT CCC TGT-39, Reverse 59-CCT TAA
TGT CAC GCA CGA TTT CC-39. For mouse S100b: Forward
59-CCG GGC GAG AGG GTG ACA AG-39, Reverse 59-ACT
CAT GGC AGG CCG TGG TC -39. For mouse nestin: Forward
59-CAG CCT CCA GGA GCG CAG AG-39, Reverse 59-TCA
GCC TCC AGC AGA GTC CTG T-39. For mouse SREBF1:
Forward 59-CCT GGA TTT GGC CCG GGG AG-39, Reverse
59-CGG GCA TCC TTC CTC AGC CC -39. For mouse
SREBF2: Forward 59-GCC CTC TGC TGG ATG ACG CA-39,
Reverse 59-CGG GCA TCC TTC CTC AGC CC -39.For mouse
LDLR: Forward 59-GCC GGA GTT GCA GCA GAA GAC-39,
Reverse 59-ACA CGG CCT CCA CAG CTG AA -39. For mouse
NSDHL: Forward 59-GTC CCC TCC GCC GTA CAG TAA C-
39, Reverse 59-CGT TGG CAT CCA GTA CTG CTC TCT-39.
For mouse HMGCR: Forward 59-GGC CTC TTC GTG GCC
TCC C-39, Reverse 59-CGC TGC TCA GCA CGT CCT CT-39.
For mouse Beta Actin: Forward 59-AGG CAC CAG GGT GTG
ATG GTG-39, Reverse 59-GGG CCA CAC GCA GTC CAT
TG -39. Beta Actin was used for normalization. Relative gene
expression was analyzed using the comparative Ct method
(22DDCt). All measurements were done in triplicates. Student’s t-
test was performed to compare the fold changes.
Protein extraction
Cells were washed with cold PBS and harvested by rapid and
gentle trypsinization at room temperature. Pellets were washed
twice with cold PBS and lysed in whole cell extraction buffer
containing 20 mM hepes, pH 7.9, 0.4 M NaCl, 25% glycerol,
1 mM EDTA, 0.5 mM DTT, 1 mM PMSF, 0.5 mM NaF,
0.5 mM Na3VO4 supplemented with 2 mg/ml aprotinin, 2 mg/
mL leupeptin, 0.3 mg/ml benzamidinchlorid,10 mg/ml trypsin
inhibitor by freezing and thawing. Supernatants were collected by
centrifugation at 10000 g for 20 min at 4uC and stored at 280uC.
The protein concentration of the supernatant was determined by
the Bradford assay.
Western blot
Aliquots of 10 mg of protein were denatured at 95uC for 5 min
and applied on a SDS–polyacrylamide gel. Proteins separated on
the gel were transferred onto PVDF membranes. For immuno-
detection, antibodies specific for the following proteins were used:
rabbit polyclonal antibody against phospho-S6 ribosomal protein
S240/244 (1:1,000, Cell Signaling, 2215, USA) and rabbit
monoclonal antibody against phospho-Akt S473 (1:1,000, Cell
Signaling, 4060, USA). Antibodies were detected using anti-rabbit
IgG, an HRP-linked heavy and light chain antibody from goat
(1:10,000, Bethyl, A120-101P) according to the supplier’s protocol.
Signals were detected using the Pierce ECL Western Blotting
Substrate (Thermo Fisher Scientific, USA) and GAPDH was used
as a loading control.
Filipin fluorescence staining in cultured cells
Cells cultured on chamber slides (Lab-Tek, Denmark) were
fixed in 4% (w/v) paraformaldehyde at room temperature for
30 min. After fixation, cells were treated with 1.5 mg/ml glycine
diluted in PBS for 10 min at room temperature to quench the
paraformaldehyde. Afterwards cells were washed 3 times with PBS
and incubated with 0.05 mg/ml filipin complex in PBS working
solution (Sigma-Aldrich, USA) for 2 hours at room temperature.
Cells were washed 3 times with PBS and staining was observed
using fluorescence microscope (Zeiss, Germany).
Data and statistical analysis
All experiments were performed in triplicate and representative
blots are shown. Data were averaged, unless otherwise specified,
and are presented as mean 6 SEM. Significant differences
between groups were tested by Student’s unpaired t-test and p,
0.05 was considered as significant.
Results
Differentiation of human monoclonal AFS cells towards
Schwann cells
In this study, we used the previously described Q1 and CD117/
2 AFS cell lines which were isolated via magnetic bead isolation
selecting for c-kit positive cells [21,22]. The Q1 cell line has been
established as a monoclonal line, whereas the CD117/2 is a pool
of cells. Therefore, we established single cell clones and selected
the monoclonal line CD117/2-I for further studies since it showed
the strongest Oct-4 expression (Fig. S1). Both AFS cell lines were
used in this study to induce a pre-myelination Schwann cell
phenotype via a novel three step differentiation protocol (Fig. 1).
AFS cells initially displayed a uniform phenotype with a low
cytoplasm to nucleus ratio and omnidirectional protruding
filopodia. During 15 days of differentiation, AFS cells increased
their cellular volume and displayed an elongated phenotype
(Fig. 2A). To examine differentiation, we monitored expression of
the established Schwann cell markers NGFR, GFAP and S100b
by immunofluorescent staining and by quantitative RT-PCR
(Fig. 2B and Fig. 2C).
During Schwann cell development also genes for lipid synthesis
are up-regulated. This is regarded as a key element in the
differentiation process, because subsequent formation of myelin is
depending on the availability of lipids. SREBF1 (encoded by the
isoforms Srebp1a and Srebp1c) and SREBF2 (encoded by Srebp2)
are transcription factors that play a major role in cholesterol
Early Schwann Cell Differentiation of Amniotic Fluid Stem Cells
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synthesis and regulate the expression of LDLR, HMGCR, and
NSDHL. While HMGCR is responsible for the internal
cholesterol biosynthesis, LDLR conveys cholesterol from outside
into the cell [23]. NSDHL is an enzyme dependent on
nicotinamide adenine dinucleotide, which functions as a sterol
dehydrogenase in cholesterol synthesis [16]. Quantitative RT-
PCR analysis revealed significant up regulation of these genes by
day 15 of differentiation, indicating uptake as well as synthesis of
cholesterol at this time point (Fig. 2C). These results suggest that
monoclonal AFS cells can be differentiated to early Schwann cells
by our protocol.
Rapamycin-sensitive mTOR is critical for Schwann cell
differentiation from AFS cells
To investigate whether mTOR signaling is involved in the
regulation of human AFS cell differentiation to Schwann cells, we
studied mTOR effector activation during the differentiation
process. Initially AFS cells grown in Chang Medium display
strong S6 phosphorylation. When differentiated, S6 phosphoryla-
tion is low on day 5 and on day 8, coinciding with a drop of total
S6 protein on day 8, which was followed by a reactivation of
mTOR activity until day 15 (Fig. 3A). Rapamycin, a selective
mTORC1 inhibitor, was used from day 5 onwards and a
concentration of 25 nM was sufficient to induce a complete block
of S6 phosphorylation (Fig. 3A). In contrast, AKT phosphoryla-
tion was up-regulated compared to the undifferentiated AFS cells
at all time points and rapamycin further enhanced its phosphor-
ylation (Fig. 3A).
To analyze the functional role of mTORC1 during Schwann
cell differentiation, we simultaneously examined NGFR expression
and S6 phosphorylation. We detected co-expression of this
Schwann cell marker in 42%612 of all pS6 positive cells (Fig. 3B).
Marker expression as well as S6 phosphorylation could be blocked
completely by rapamycin treatment (Fig. 3B). Furthermore,
rapamycin treatment from day 5 until day 15 of differentiation
resulted in a marked decrease of the cell size as well as a decrease
Figure 1. Scheme for the applied differentiation protocol. In
order to initiate human AFS cell differentiation to a Schwann cell
phenotype AFS cells were first treated in serum free a-MEM with 1 mM
b-mercaptoethanol (Diff. I) for 24 hours. Afterwards cells were
incubated in a-MEM supplemented with 10% fetal bovine serum and
35 ng/ml retinoic acid (Diff. II) for 72 hours. Subsequently, cells were
cultured in a-MEM containing 10% fetal bovine serum supplemented
with 20 ng/mL epidermal growth factor, 20 ng/mL basic fibroblast
growth factor, 5 mM forskolin, 5 ng/mL platelet-derived growth factor-
AA and 200 ng/mL recombinant human heregulin-beta1 (Diff. III) until
day 15 of differentiation. Media was changed every 3 days, indicated by
arrows. Pharmacologic (pharm.) treatment, consisting of rapamycin or
statin, was applied together with Diff. III media.
doi:10.1371/journal.pone.0107004.g001
Figure 2. Human monoclonal amniotic fluid stem cells can be
differentiated into a early Schwann cell phenotype. (A) AFS cells
are small cells with omnidirectional protruding filopodia and upon
differentiation to Schwann-like cells, at day 15 of treatment, cells
exhibited an increase in cellular volume and an elongated cell
morphology. Scale bar represents 50 mm. (B) Immunofluorescence
staining of AFS cells differentiated for 15 days (dAFS) compared to
undifferentiated AFS cells (AFS) and MCM1 neural crest-derived cells
(control), for the Schwann cell markers NGFR, GFAP and S100b (labeled
in red, nuclei labeled in green). Purity of cells is indicated as percent
positive cells versus total amount of cells 6 S.D. Scale bar represents
10 mm. (C) Quantitative RT-PCR of cDNA derived from AFS cells and
from AFS cells subjected to Schwann cell differentiation after different
time points was performed. Results are shown as fold change
expression of respective genes compared to undifferentiated AFS cells.
The results are expressed as means 6 SEM of three independent
experiments. P,0.05 for * vs undifferentiated AFS cells.
doi:10.1371/journal.pone.0107004.g002
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in the availability of free cholesterol (Fig. 3C). Importantly,
rapamycin did not reduce cellular viability during long term
treatment (Fig. S2). These results suggested that mTORC1 is
essential for early Schwann cell differentiation.
Figure 3. mTOR signaling is active in differentiated AFS cells
and important for the differentiation process. (A) AKT phosphor-
ylation at Ser 473 and ribosomal protein S6 phosphorylation at Ser 240/
244 were quantified at the indicated time points during differentiation
with and without rapamycin treatment. (B) NGFR, a marker for early
differentiated AFS cells (labeled in green), was co-stained with
phosphorylated S6 at Ser 240/244 protein (labeled in red) with and
without rapamycin treatment (nuclei labeled in blue). Scale bar
represents 10 mm. (C) Accumulation of free cholesterol was monitored
by filipin III staining. Scale bar represents 10 mm.
doi:10.1371/journal.pone.0107004.g003
Figure 4. Rapamycin treatment down-regulates Schwann cell
marker expression in differentiated human AFS cells and in
sciatic nerves from juvenile mice. (A) Quantitative RT-PCR of cDNA
derived from AFS cells differentiated towards Schwann cells for 15 days
with and without rapamycin was performed to assess Schwann cell
marker expression. Results are shown as fold change of respective gene
expression from rapamycin-treated cells compared to control treated
cells. (B) Sciatic nerves were isolated from everolimus- or control-treated
mice and cDNA generated thereof was assessed for Schwann cell
marker expression. Results are shown as fold change of respective gene
expression from everolimus-treated mice compared to control-treated
mice. The results are expressed as means 6 SEM of three independent
experiments. P,0.05 for * vs control treated cells or animals. (C) Sciatic
nerves from untreated or treated mice were subjected to Luxol fast blue
staining and immunohistochemical staining for S100b and S6
phosphorylation was performed (stained in red, nuclei in blue). Panel
in upper right shows control treated sciatic nerve tissue stained for
active S6 protein (red) and nuclei (blue), insert shows control antibody
staining. Scale bar represents 20 mm.
doi:10.1371/journal.pone.0107004.g004
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Schwann cell-expressed genes are down-regulated after
rapamycin treatment in human AFS cells in vitro and in
sciatic nerves from juvenile mice in vivo
To further investigate the role of mTORC1 on the regulation of
human AFS cells to Schwann cell differentiation, quantitative RT-
PCR analysis was performed. Continuous rapamycin treatment
from day 5 onwards resulted in the down regulation of S100b and
nestin at day 15 of differentiation. The transcription factors
SREBF1 and SREBF2 were not significantly down-regulated
during treatment, but their targets NSDHL, LDLR and HMGCR
were strongly reduced (Fig. 4A).
To analyze the role of mTORC1 in Schwann cells in vivo, we
treated 7 weeks-old mice with the mTORC1 inhibitor everolimus
for 4 weeks. Schwann cells are fully myelinated by 7 weeks of age,
but motor nerve conduction velocity of mice is still gradually
increasing until week 10 [24]. Sciatic nerves from 7 everolimus-
treated and 6 age-matched control mice were isolated and
quantitative RT-PCR analysis showed a decrease of S100b and
nestin (Fig. 4B). The levels of LDLR, HMGCR and NSDHL were
also significantly decreased (Fig. 4B). Measuring myelin thickness
and axonal packing with ImageJ on Luxol fast blue stained
sections revealed no significant changes (data not shown), even
though active S6 was localized within myelin containing areas and
everolimus treatment efficiently blocked S6 protein phosphoryla-
tion (Fig. 4C). Additionally, expression of S100b, which resides
mainly in the nucleus, was slightly reduced as visualized by
immunohistochemistry (Fig. 4C).
Lipogenic gene expression promotes human AFS to
Schwann cell differentiation
Next, we tested whether increasing the expression of lipogenic
genes can directly influence early Schwann cell differentiation. We
employed lovastatin, a competitive HMGCR inhibitor, which
initially blocks cholesterol synthesis and reduces cellular choles-
terol. As a consequence it promotes the activation of SREBPs,
increases the expression of lipogenic genes including the LDLR
and promotes LDL and cholesterol uptake in lipid-rich media
[25]. In all our experiments statin treatment resulted, as expected,
in the enhanced expression of LDLR, HMGCR and NSDHL
mRNA (Fig. 5A) and protein (Fig. 5B, 5C and Fig. S3).
Surprisingly, statin treatment until day 15 of differentiation
resulted in a strong up regulation of S100b and nestin mRNA
compared to control treated cells (Fig. 5A). Immunofluorescence
analysis showed characteristic localization of GFAP at intermedi-
ate filament bundles and LDLR as dot like structures at the
membrane and inside of cells, in control and statin treated groups
(Fig. 5B). Western blotting confirmed reduced expression of the
Schwann cell marker GFAP and the SREBP target LDLR upon
rapamycin treatment (Fig. 5C), whereas statin treatment increased
GFAP and LDLR together with an elevated phosphorylation of S6
(Fig 5C). These results suggest that the induction of lipogenic
genes can enhance early Schwann cell differentiation from AFS
cells.
S6K1 promotes S100b expression, but not lipogenic
genes in differentiating human AFS cells
To explore pathways downstream of mTORC1 a constitutively
active HA-tagged S6K1 mutant was used, which maintains its
activity in the presence of rapamycin [26]. The S6K1 mutant was
transfected into AFS cells differentiated for 15 days and cells were
maintained in differentiation media either with or without
rapamycin for 72 hours. As expected, transfected cells showed
S6 phosphorylation, in contrast to un-transfected neighboring
cells, indicating correct function of the expression construct
(Fig. 6A, 6B lower panel). HA-positive cells re-established strong
expression of S100b, the most consistently expressed Schwann cell
Figure 5. Rapamycin decreases Schwann cell markers, whereas
statin induces Schwann cell markers. (A) During the last 72 hrs of
differentiation, AFS cells were treated with 5 mM and 10 mM statin. After
15 days cDNA was generated and used for quantitative PCR of
respective genes. The results are expressed as means 6 SEM of three
independent experiments. P,0,05 for * vs control treated cells. (B) AFS
cells were differentiated for 15 days and since day 5 continuously
treated either with 25 nM rapamycin or 1 mM of statin. Fixed cells were
stained with indicated antibodies (labeled in red, nuclei in green). Scale
bar represents 10 mm. (C) Western blotting of cells differentiated for 15
days and since day 5 continuously treated either with 25 nM rapamycin
or 1 mM of statin. GFAP was detected at about 50 kDa, LDLR at 160 kDa
and HMGCR as a double band at 90 kDa.
doi:10.1371/journal.pone.0107004.g005
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marker available, even in the presence of rapamycin (Fig. 6A, 6B).
In contrast, the lipogenic markers LDLR and HMGCR were not
rescued by the S6K1 mutant in the presence of rapamycin
(Fig. 6B,). We also overexpressed wild type S6K1 and detected a
consistent increased expression of GFAP and NGFR, but not of
nestin (Fig. S4). A TOS motive mutated S6K1 (HA-S6K1-F5A),
which strongly inhibits S6 activation [27], was not able to increase
S100b expression (Fig. S5). This indicates that during AFS
differentiation Schwann cell-specific S100b, GFAP and NGFR are
positively regulated by mTORC1 through S6K1, whereas
lipogenic gene expression is dependent on mTORC1, but
independent from S6K1 as summarized in Figure 7.
Discussion
Here we analyzed early steps during monoclonal AFS cell
differentiation towards Schwann cells and whether this differen-
tiation depends on mTORC1. Cells derived from the amniotic
fluid originate from the developing fetus and are therefore a
mixture of different cell types. To our knowledge, here we show for
the first time that c-kit selected monoclonal AFS cells can be
induced by a three step protocol to express classic Schwann cell
markers like NGFR, GFAP, nestin and S100b.
We cultured the cells for 15 days, which is comparable to the
time period needed for human bone marrow derived mesenchy-
mal stem cells to express Schwann cell markers [28]. We could
show that this time period is sufficient to monitor SREBP target
gene activation. The up regulation of lipogenic genes like NSDHL,
LDLR and HMGCR recapitulates the developmental process
monitored during in vivo Schwann cell maturation and has been
shown in rats and mice [14,29]. During post-natal development
glial cells of the peripheral nervous system start to ensheath axons
and hence, need to synthesize large amounts of myelin [30]. In
protein lysates from sciatic nerves of new born mice strong S6
activation was shown, correlating with the time point of strongest
myelin synthesis [31,32]. 71% of the myelin membrane is
composed of lipids and one of the most abundant form of lipids
in the membrane is cholesterol [33]. Sterol regulatory element-
binding protein, a protein necessary for SREBP processing, has
been shown to be required for the myelination process, since its
loss resulted in hypomyelination and abnormal gait [15].
Therefore, the induction of lipogenic genes can be considered a
hallmark of functional Schwann cell development. We showed
that during differentiation of AFS cells ribosomal protein S6 was
phosphorylated and that this activation correlated with expression
of NGFR, a prototype early Schwann cell marker. On the
contrary, inhibition of S6 phosphorylation by rapamycin led to a
decrease in Schwann cell marker expression, a reduction in free
cholesterol accumulation and a down regulation of SREBP target
Figure 6. Rapamycin resistant S6K1 induces S100b, but not
LDLR or HMGCR expression. (A) AFS cells were differentiated
without or (B) in the presence of rapamycin and at day 15 cells were
transfected with an HA-fused S6K1 rapamycin-resistant mutant (HA-
S6K1-RR). After 72 hours in differentiation media containing rapamycin,
cells were fixed and stained with anti-HA antibody (shown in green)
combined with antibodies detecting S100b, LDLR, HMGCR and
phosphorylated S6 (shown in red). Scale bar represents 25 mm.
doi:10.1371/journal.pone.0107004.g006
Figure 7. Model of mTORC1 involvement in Schwann cell
differentiation. Rapamycin blocks mTORC1 and results in the down
regulation of Schwann cell markers (e.g.: S100b) and in the down
regulation of lipogenic genes (e.g.: LDLR, HMGCR). Our data indicates
that S6K1 regulates the expression of S100b, but not of LDLR and
HMGCR.
doi:10.1371/journal.pone.0107004.g007
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genes. Rapamycin treatment of mice resulted in a decrease of
Schwann cell differentiation and lipogenic marker expression on
the RNA level in sciatic nerves in vivo. We could not detect
changes in myelin composition of everolimus treated versus
untreated sciatic nerves probably because myelination is already
completed 7 weeks after birth. It was shown that myelin as well as
overall protein translation is down regulated during maturation of
peripheral nerves and that expression of the Mek1DD allel, which
induces MAPK activation and also mTOR activation, can
override the termination of myelin growth [32]. In this model
myelinisation proceeds until P90 and treatment with rapamycin
from P17 to P30 strongly reduced myelin growth and axonal
packing, when compared to vehicle treated controls.
Since rapamycin treatment resulted in a suppression of SREBP
target genes, which regulate both synthesis and uptake of
cholesterol, we next blocked only cholesterol synthesis. Lovastatin
was used to inhibit HMG-CoA reductase and, as expected,
lipogenic marker genes were up regulated in response to the
treatment, but surprisingly, also Schwann cell markers were
enhanced. This suggests that lipid uptake, but not cholesterol
synthesis is important for Schwann cell differentiation. Important-
ly, our results also suggest that for in vitro protocols, statins might
promote differentiation of AFS cells or other stem cells into
Schwann cells. This phenomenon could be due to the induction of
LDLR expression and other lipid receptors in the presence of
lipid-rich media. This enables differentiating cells to take up lipids
essential for cellular homeostasis, which can support Schwann cell
differentiation and may additionally induce cell signaling pathways
like mTOR driven S6 kinase activation. So far, little is known on
the role of LDLR for mTOR activation, but there is evidence that
lipid receptors play a role during regeneration of peripheral nerves
after injury [34]. Also in oligodendrocytes LDLR and VLDLR
play an important role in the formation of the myelin sheath [35].
Studies have shown that statins, which up-regulate lipid receptors,
are not toxic to rat Schwann cells in vitro and that they can induce
myelin-like membranes in primary rat oligodendrocytes [36,37].
Statins can even augment survival and differentiation of
oligodendrocytes in an animal model of multiple sclerosis [38].
We rescued the rapamycin induced phenotype by overexpress-
ing rapamycin resistant S6K1. This re-established S6 phosphor-
ylation and led to increased Schwann cell differentiation
exemplified by S100b expression. Still it could not re-establish
lipogenic gene expression as demonstrated by lack of HMGCR
and LDLR expression. This suggests that mTORC1 is important
for the expression of Schwann cell markers and lipogenic genes,
but the later are regulated independently of S6K1. Mice lacking
mTOR in Schwann cells have been analyzed and they display
postnatal growth retardation of myelinating Schwann cells, both
radially and longitudinally [1]. Furthermore, Peterson et. al could
show that mTOR directly regulates SREBP activity by controlling
localization of lipin 1 [39]. These results support our finding of
S6K1-independent regulation of lipogenic genes during early
differentiation of AFS cells to Schwann cells.
Taken together, we have shown that rapamycin negatively
regulates AFS cell differentiation to Schwann cells. We suggest
that lipid uptake is an important process for efficient Schwann cell
differentiation and that rapamycin-sensitive mTORC1 can
regulate lipogenic gene expression independent of S6K1, whereas
S6K1 activation is important for Schwann cell marker expression.
Our findings propose that rapamycin, which is routinely used in
clinical practice because of its immunosuppressive effects, has the
potential to perturb Schwann cell function. Others have already
noted that rapamycin is not at all a neuroregeneration promoting
agent during studies in mice on peripheral nerve allografting [40].
We suggest that successful strategies for tissue regeneration therapy
or regeneration after injury in the peripheral nervous system will
depend on ways to efficiently induce the mTOR-S6K pathway.
Our results further suggest statins as potential novel drugs to
enhance early Schwann cell differentiation in vitro.
Supporting Information
Figure S1 CD117/2 amniotic fluid stem cells were single cell
cloned by limiting dilution. Single cell clone CD117/2-I displayed
a normal propidium iodide stain, as observed in the starting
population CD117/2. CD117/2-I exhibited a small and uniform
cell morphology characteristic for bona fide amniotic fluid stem
cells. Immunofluorescence staining with the santa cruz antibody
sc-5789 revealed a strong nuclear Oct-4 stain in CD117/2-I cells
similar to Ntera-2 carcinoembryonal cells used as control cells.
Single cell clone CD117/2-A is shown as an unsuitable cell line,
which displayed abnormal propidium iodide stain, heterogeneous
and large cells in culture and no Oct-4 stain. Scale bar represents
5 mm. PI-FACs = propidium iodide fluorescence activated cell
scanning.
(TIF)
Figure S2 Starting from day 5 of differentiation the effect of
25 nM rapamycin on cell viability was measured by using Alamar
blue. Cells were seeded equally on day 5 of differentiation and
continued to be treated with differentiation media III (see Fig. 1)
either with or without the addition of rapamycin. Alamar blue was
added and cells were incubated for an additional 4 hours. The
fluorescence was measured at wavelengths excitation 540 nm and
emission 590 nm. The average out of 4 measurments is shown
+/2 S.D.
(TIF)
Figure S3 AFS cells were differentiated for 15 days and
continuously treated either with 25 nM rapamycin or 1 mM of
statin. Fixed cells were stained with indicated antibodies (labeled in
red, nuclei in green). Scale bar represents 10 mm.
(TIF)
Figure S4 AFS cells were differentiated as described in material
and methods and at day 15 cells were transfected with an HA-
fused wild type S6K1 (HA-S6K1) purchased from Addgene. After
72 hours in differentiation media cells were fixed and stained with
anti-HA antibody (shown in green) combined with antibodies
detecting Nestin, GFAP, NGFR and phosphorylated S6 (shown in
red). Rapa = Rapamycin treatment for 72 hours. AB ctr =
antibody control stain. Scale bar represents 25 mm.
(TIF)
Figure S5 AFS cells were differentiated as described in material
and methods and at day 15 cells were transfected with an HA-
fused TOS motive mutated S6K1 (HA-S6K1-F5A), purchased
from Addgene. After 72 hours in differentiation media cells were
fixed and stained with anti-HA antibody (shown in green)
combined with antibodies detecting S100b, LDLR, HMGCR
and phosphorylated S6 (shown in red). Rapa = Rapamycin
treatment for 72 hours. AB ctr = antibody control stain. Scale bar
represents 25 mm.
(TIF)
Acknowledgments
The authors thank Jelena Brankovic for excellent technical assistance.
Early Schwann Cell Differentiation of Amniotic Fluid Stem Cells
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e107004
Author Contributions
Conceived and designed the experiments: MM MH GL HS. Performed
the experiments: AP KL DS HTTP. Analyzed the data: MM TW KK BS
GJJ CR. Contributed reagents/materials/analysis tools: MR CR TW GJJ
HS GL MH. Contributed to the writing of the manuscript: MM KL AP.
Obtained permission for use of cell line: MH MR.
References
1. Sherman DL, Krols M, Wu LM, Grove M, Nave KA, et al. (2012) Arrest of
myelination and reduced axon growth when Schwann cells lack mTOR.
J Neurosci 32: 1817–1825.
2. Martin I, Nguyen TD, Krell V, Greiner JF, Muller J, et al. (2012) Generation of
Schwann cell-derived multipotent neurospheres isolated from intact sciatic
nerve. Stem Cell Rev 8: 1178–1187.
3. Liang C, Tao Y, Shen C, Tan Z, Xiong WC, et al. (2012) Erbin is required for
myelination in regenerated axons after injury. J Neurosci 32: 15169–15180.
4. Ladak A, Olson J, Tredget EE, Gordon T (2011) Differentiation of
mesenchymal stem cells to support peripheral nerve regeneration in a rat
model. Exp Neurol 228: 242–252.
5. Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschlager M (2003) Oct-
4-expressing cells in human amniotic fluid: a new source for stem cell research?
Hum Reprod 18: 1489–1493.
6. In ’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH,
et al. (2003) Amniotic fluid as a novel source of mesenchymal stem cells for
therapeutic transplantation. Blood 102: 1548–1549.
7. Prusa AR, Marton E, Rosner M, Bettelheim D, Lubec G, et al. (2004)
Neurogenic cells in human amniotic fluid. Am J Obstet Gynecol 191: 309–314.
8. Tsai MS, Lee JL, Chang YJ, Hwang SM (2004) Isolation of human multipotent
mesenchymal stem cells from second-trimester amniotic fluid using a novel two-
stage culture protocol. Hum Reprod 19: 1450–1456.
9. Kim J, Lee Y, Kim H, Hwang KJ, Kwon HC, et al. (2007) Human amniotic
fluid-derived stem cells have characteristics of multipotent stem cells. Cell Prolif
40: 75–90.
10. De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, et al. (2007)
Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol
25: 100–106.
11. Valli A, Rosner M, Fuchs C, Siegel N, Bishop CE, et al. (2010) Embryoid body
formation of human amniotic fluid stem cells depends on mTOR. Oncogene 29:
966–977.
12. Brohlin M, Mahay D, Novikov LN, Terenghi G, Wiberg M, et al. (2009)
Characterisation of human mesenchymal stem cells following differentiation into
Schwann cell-like cells. Neurosci Res 64: 41–49.
13. Tian X, Wang S, Zhang Z, Lv D (2012) Rat bone marrow-derived Schwann-like
cells differentiated by the optimal inducers combination on microfluidic chip and
their functional performance. PLoS One 7: e42804.
14. Leblanc SE, Srinivasan R, Ferri C, Mager GM, Gillian-Daniel AL, et al. (2005)
Regulation of cholesterol/lipid biosynthetic genes by Egr2/Krox20 during
peripheral nerve myelination. J Neurochem 93: 737–748.
15. Verheijen MH, Camargo N, Verdier V, Nadra K, de Preux Charles AS, et al.
(2009) SCAP is required for timely and proper myelin membrane synthesis. Proc
Natl Acad Sci U S A 106: 21383–21388.
16. Sharpe LJ, Brown AJ (2013) Controlling cholesterol synthesis beyond 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGCR). J Biol Chem 288: 18707–18715.
17. Bakan I, Laplante M (2012) Connecting mTORC1 signaling to SREBP-1
activation. Curr Opin Lipidol 23: 226–234.
18. Chen WQ, Siegel N, Li L, Pollak A, Hengstschlager M, et al. (2009) Variations
of protein levels in human amniotic fluid stem cells CD117/2 over passages 5–
25. J Proteome Res 8: 5285–5295.
19. Swoboda A, Schanab O, Tauber S, Bilban M, Berger W, et al. (2012) MET
expression in melanoma correlates with a lymphangiogenic phenotype. Hum
Mol Genet 21: 3387–3396.
20. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25
years of image analysis. Nat Methods 9: 671–675.
21. Fuchs C, Rosner M, Dolznig H, Mikula M, Kramer N, et al. (2012) Tuberin and
PRAS40 are anti-apoptotic gatekeepers during early human amniotic fluid stem-
cell differentiation. Hum Mol Genet 21: 1049–1061.
22. Siegel N, Rosner M, Unbekandt M, Fuchs C, Slabina N, et al. (2010)
Contribution of human amniotic fluid stem cells to renal tissue formation
depends on mTOR. Hum Mol Genet 19: 3320–3331.
23. Calandra S, Tarugi P, Speedy HE, Dean AF, Bertolini S, et al. (2011)
Mechanisms and genetic determinants regulating sterol absorption, circulating
LDL levels, and sterol elimination: implications for classification and disease risk.
J Lipid Res 52: 1885–1926.
24. King RH, Chandler D, Lopaticki S, Huang D, Blake J, et al. (2011) Ndrg1 in
development and maintenance of the myelin sheath. Neurobiol Dis 42: 368–380.
25. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL (1983) Mevinolin and
colestipol stimulate receptor-mediated clearance of low density lipoprotein from
plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad
Sci U S A 80: 4124–4128.
26. Schalm SS, Tee AR, Blenis J (2005) Characterization of a conserved C-terminal
motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian
target of rapamycin-dependent regulation. J Biol Chem 280: 11101–11106.
27. Schalm SS, Blenis J (2002) Identification of a conserved motif required for
mTOR signaling. Curr Biol 12: 632–639.
28. Caddick J, Kingham PJ, Gardiner NJ, Wiberg M, Terenghi G (2006) Phenotypic
and functional characteristics of mesenchymal stem cells differentiated along a
Schwann cell lineage. Glia 54: 840–849.
29. Fu Q, Goodrum JF, Hayes C, Hostettler JD, Toews AD, et al. (1998) Control of
cholesterol biosynthesis in Schwann cells. J Neurochem 71: 549–555.
30. Wegner M (2000) Transcriptional control in myelinating glia: flavors and spices.
Glia 31: 1–14.
31. Heller BA, Ghidinelli M, Voelkl J, Einheber S, Smith R, et al. (2014)
Functionally distinct PI 3-kinase pathways regulate myelination in the peripheral
nervous system. J Cell Biol 204: 1219–1236.
32. Sheean ME, McShane E, Cheret C, Walcher J, Muller T, et al. (2014)
Activation of MAPK overrides the termination of myelin growth and replaces
Nrg1/ErbB3 signals during Schwann cell development and myelination. Genes
Dev 28: 290–303.
33. Chrast R, Saher G, Nave KA, Verheijen MH (2011) Lipid metabolism in
myelinating glial cells: lessons from human inherited disorders and mouse
models. J Lipid Res 52: 419–434.
34. Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, et al. (1989) A role
for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors
in cholesterol transport during regeneration and remyelination of the rat sciatic
nerve. J Clin Invest 83: 1015–1031.
35. Zhao S, Hu X, Park J, Zhu Y, Zhu Q, et al. (2007) Selective expression of LDLR
and VLDLR in myelinating oligodendrocytes. Dev Dyn 236: 2708–2712.
36. Maier O, De Jonge J, Nomden A, Hoekstra D, Baron W (2009) Lovastatin
induces the formation of abnormal myelin-like membrane sheets in primary
oligodendrocytes. Glia 57: 402–413.
37. Murinson BB, Haughey NJ, Maragakis NJ (2012) Selected statins produce rapid
spinal motor neuron loss in vitro. BMC Musculoskelet Disord 13: 100.
38. Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, et al. (2005) HMG-
CoA reductase inhibitor augments survival and differentiation of oligodendro-
cyte progenitors in animal model of multiple sclerosis. FASEB J 19: 1407–1421.
39. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, et al. (2011)
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway.
Cell 146: 408–420.
40. Myckatyn TM, Ellis RA, Grand AG, Sen SK, Lowe JB, 3rd, et al. (2002) The
effects of rapamycin in murine peripheral nerve isografts and allografts. Plast
Reconstr Surg 109: 2405–2417.
Early Schwann Cell Differentiation of Amniotic Fluid Stem Cells
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e107004
